Experimental validation of an innovative approach in biokinetics study for personalised dosimetry of molecular radiation therapy treatments

One of today’s main challenges in molecular radiation therapy is to assess an individual dosimetry that allows treatment to be tailored to the specific patient, in accordance with the current paradigm of ‘personalized medicine’. The evaluation of the absorbed doses for tumor and organs at risk in molecular radiotherapy is typically based on MIRD schema acquiring few experimental points for the assessement of biokinetic parameters. WIDMApp, the wearable individual dose monitoring apparatus, is an innovative approach for internal dosimetry based on a wearable radiation detecting system for individual biokinetics sampling, a Monte Carlo simulation for particle interaction, and an unfolding algorithm for data analysis and integrated activity determination at organ level. A prototype of a WIDMApp detector element was used to record the photon emissions in a body phantom containing 3 spheres with liquid sources (18F, 64Cu and 99m Tc) to simulate organs having different washout. Modelling the phantom geometry on the basis of a CT scan imaging, the Monte Carlo simulation computed the contribution of each emitting sphere to the signal detected in 3 positions on the phantoms surface. Combining the simulated results with the data acquired for 120 h, the unfolding algorithm deconvolved the detected signal and assessed the decay half-life (T 1/2) and initial activity values (A(0)) that best reproduces the observed exponential decays. A 3%–18% level of agreement is found between the actual A(0) and T 1/2 values and those obtained by means of the minimization procedure based on the Monte Carlo simulation. That resulted in an estimation of the cumulated activity <15%. Moreover, WIDMApp data redundancy has been used to mitigate some experimental occurrences that happened during data taking. A first experimental test of the WIDMApp approach to internal radiation dosimetry is presented. Studies with patients are foreseen to validate the technique in a real environment.

[1]  L. Strigari,et al.  Evolution of Portable Sensors for In-Vivo Dose and Time-Activity Curve Monitoring as Tools for Personalized Dosimetry in Molecular Radiotherapy , 2023, Sensors.

[2]  M. Pacilio,et al.  A wearable radiation measurement system for collection of patient-specific time-activity data in radiopharmaceutical therapy: system design and monte carlo simulation results. , 2021, Medical Physics (Lancaster).

[3]  S. Incerti,et al.  Report on G4-Med, a Geant4 benchmarking system for medical physics applications developed by the Geant4 Medical Simulation Benchmarking Group. , 2020, Medical physics.

[4]  Iain Murray,et al.  EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  A. Celler,et al.  MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy , 2016, The Journal of Nuclear Medicine.

[6]  Michael Ljungberg,et al.  MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications , 2013, The Journal of Nuclear Medicine.

[7]  Stephen R. Thomas,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[8]  Michael G Stabin,et al.  Update: the case for patient-specific dosimetry in radionuclide therapy. , 2008, Cancer biotherapy & radiopharmaceuticals.

[9]  Michael Lassmann,et al.  The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. , 2006, Zeitschrift fur medizinische Physik.

[10]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..